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Abstract
The publication of the results of the Swedish Trial in Old Patients with Hypertension-2
(STOP-2) and the termination of the doxazocin arm of the Antihypertensive and Lipid
Lowering Treatment to Prevent Heart Attack (ALLHAT) study again raise the question of
whether all antihypertensives deliver equal cardiovascular outcome benefits. Data from
research on congestive heart failure and from the Heart Outcomes Prevention Evaluation
(HOPE) trial illuminate the roles and possible mechanisms of humoral mediators of vascular
damage, suggesting, first, that some antihypertensives (thiazides, beta-blockers, and
angiotensin-converting enzyme inhibitors) can deliver more improvement in outcomes than
other agents and, second, that decisions on whom to treat are best made based on risk
appraisal, not merely pressures.
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These are exciting times for physicians interested in the
treatment of hypertension, with new and important data
emerging regularly. Translating the excitement into better
outcomes for large numbers of patients, however, means
placing the new information in the hands of generalist
physicians (family physicians and general internists), and
making the information clear enough to be usable rather
than baffling. Hypertension practice guidelines should
accomplish this information placement, but recent guide-
lines based on the most recent evidence reach conflicting
conclusions in some ways [1–3]. The conflict centers
around two key issues: does it matter how blood pressure
is lowered?; and are there subsets of patients who benefit
from antihypertensive drugs at lower pressures than we
have conventionally believed, or who do not benefit unless
pressures are higher than we have believed?
Two recent trials offer what appears to be confusing guid-
ance on the first question. STOP-2 [4] compared newer
and older antihypertensive agents, and concluded that
there were no substantial differences in outcomes among
them. This finding lends credence to the conventional view
http://cvm.controlled-trials.com/content/1/1/022
com
m
entary
review
reports
prim
ary research
that blood pressure is the factor that matters, and lowering
it by any means that has acceptably low side effect rates is
the appropriate approach. Not long after the publication of
STOP-2, however, the doxazocin arm of the ALLHAT trial
was terminated because of an excessive rate of develop-
ment of congestive heart failure compared with thiazides
[5], suggesting that how blood pressure is lowered may
indeed matter in terms of outcomes achieved. What is the
primary care physician to make of these developments?
The ‘pressure is what counts’ view is attractive. It offers
simplicity, and great flexibility in clinical choices: any
treatment that reduces pressures and is acceptable to
patients is a good treatment for hypertension. It is tempt-
ing to think that the ALLHAT findings may be an anomaly,
or perhaps specific to doxazocin, and that the conclusion
of STOP-2 is the correct one. Closer examination,
however, suggests that this conclusion is not prudent.
STOP-2 did not really find that all the regimens were
similar. It rather showed an excess of both myocardial
infarction and congestive heart failure (CHF) in the
calcium antagonist arm as compared with the angiotensin-
converting enzyme (ACE) inhibitor arm, a finding attributed
to chance due to the total of 48 such comparisons made.
The similarity of that finding to the results of the earlier
Appropriate Blood Pressure Control in Diabetes (ABCD)
trial [6], however, lends support to the argument that it
was not a chance occurrence. Furthermore, an excess of
myocardial infarction almost reached significance among
the conventional-therapy arm compared with that of ACE
inhibitor. Conventional therapy in STOP-2 involved thi-
azides and beta-blockers, and there is evidence from other
studies that beta-blockers are not as effective, in terms of
outcomes in the elderly, as thiazides [7].
The marked change in our understanding of CHF over the
past decade is worth considering in our thinking about
hypertension. The results of recent antihypertensive trials
are exciting, rather than being confusing and dismaying,
when seen in light of the CHF research, and offer hope of
getting closer to the real roots of the harm that hyperten-
sion does. A deeper understanding of the role of the
renin–angiotensin–aldosterone system and the patho-
physiological role of angiotensin II in vascular disease [8],
in particular, adds more credence to the view that pres-
sure per se may not be all that, or even mostly what,
matters for the hypertensive patient’s outcome. Antihyper-
tensive drugs cause many effects other than lowering
pressure, and those other effects are different for different
classes. With the emergence of data demonstrating that
ACE inhibition improves cardiovascular outcomes in high-
risk diabetics even without hypertension [9,10] and the
established efficacy of beta-blockers for CHF patients
without hypertension [11], the role of humoral rather than
merely mechanical factors in determining outcomes must
be considered by the primary care physician when choos-
ing medication therapies.
If humoral factors matter as much as or more than pres-
sure per se in determining outcomes of hypertension, we
must focus our research on interventions that affect those
humoral factors. But changing our thinking about how we
treat will not be enough. We must also think carefully
about how we decide whom to treat. Beta-blockade
improves outcome among patients with coronary artery
disease, regardless of hypertension, and, as already
noted, ACE inhibition also appears to do so for diabetics.
Trials of what we regard as antihypertensive therapy could
show improved outcomes among patients with high–
normal or even normal pressures for reasons entirely un-
related to blood pressure, if the patients enrolled had
significant baseline risks of cardiovascular disease. We
might erroneously conclude that our threshhold for diag-
nosing hypertension should be lowered, and mistakenly
extrapolate those findings to all patients above our
lowered thresholds.
So what do the findings of these most recent trials imply
for the generalist physician? First and foremost, we cannot
assume that all antihypertensive drugs are created equal.
We should preferentially prescribe for our patients those
that have demonstrated the best outcomes. At the present
time, considering these outcomes, low-dose thiazides,
beta-blockers, and ACE inhibitors should be the mainstays
of therapy. We also need additional research: direct com-
parisons of different classes of agents in randomized non-
placebo (active control) trials. Those trials must compare
real outcomes not blood pressures, and we must interpret
those trials with care. At present, low-dose thiazides set
the benchmark for outcome improvement among both
elders with systolic hypertension and middle-aged
patients with diastolic hypertension, and should be the
active controls against which other agents are measured.
Finally, and most importantly, we are moving further from a
single decision criterion for deciding whom to treat. Primary
care is a tough challenge, in which most patients have a
number of health problems and concerns. Hypertension is
only one player on the stage and, to the patient, it may not
even have the starring role. It was very helpful to have only
one number, 140/90, to remember amidst those many
competing agendas and time pressures of the primary care
visit. It was … but is no more. We have just begun becom-
ing comfortable with a different criterion for diabetics; we
must now begin looking at treating patients who are not
hypertensive by any criterion, if their cardiovascular risks
are high enough. Conversely, it may well not be worth treat-
ing some stage I hypertensive patients who are at such low
risk that their potential absolute risk reduction from treat-
ment is miniscule. Primary care physicians must shift their
thinking to treating cardiovascular risks, rather than blood
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pressure numbers, and begin to develop the decision
support models that allow this treatment in the busy, dis-
tracting, time-constrained context of primary care.
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